0001437749-21-006941.txt : 20210324 0001437749-21-006941.hdr.sgml : 20210324 20210324073121 ACCESSION NUMBER: 0001437749-21-006941 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210324 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210324 DATE AS OF CHANGE: 20210324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 21766630 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20210312b_8k.htm FORM 8-K mbrx20210312b_8k.htm
false 0001659617 0001659617 2021-03-24 2021-03-24
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 24, 2021
 
moleculin-logo_horizresizedf.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 
 
 
 
 
Item 2.02     Results of Operations and Financial Condition.
 
On March 24, 2021, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2020 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01      Financial Statements and Exhibits.
 
(d)     Exhibits.
 
Exhibit No.
Description
 
104
Cover page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC.
   
   
 
Date: March 24, 2021
   
 
By: /s/ Jonathan P. Foster
 
Jonathan P. Foster
Chief Financial Officer
 
2
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
No. Description
 
104
Cover page Interactive Data File (embedded within the Inline XBRL document)
 
 
 EX-99.1 2 ex_233629.htm EXHIBIT 99.1 ex_233629.htm

Exhibit 99.1

moleculin-logo_horizresizedf.jpg

Moleculin Biotech, Inc. Reports Financial Results

for the Year Ended December 31, 2020

 

HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended December 31, 2020 and provided a business update.

 

Recent Milestones and Accomplishments:

 

Corporate Strategy and Events

 

Raised gross proceeds of approximately $81 million through registered equity offering and ATM program in 1Q21 providing runway into 2025 based on the Company’s current R&D spending levels. The Company may expand its R&D expenditures to take advantage of new opportunities within its broad pipeline and/or increase the speed of its clinical trials. At a minimum however, the Company intends for current cash levels to support an operating runway through at least 2023.

 

Next Generation Anthracycline - Annamycin

 

●

Received $1.5 million grant to fund a Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (“STS”) lung metastases in Europe
 

●

Received FDA IND and ODD for Annamycin against STS; plan to begin a Phase 1b/2 clinical trial in the US for patients after receiving first-line therapy for STS that has metastasized to the lungs
 

●

Reached a 2nd dose limiting toxicity (DLT) in March 2021 and plan to establish a maximum tolerable dose (MTD) in our European trial for Annamycin against acute myeloid leukemia (AML); plan to pursue Phase 2 once the recommended Phase 2 dose (RP2D) is established
 

●

Presented animal data at American Society for Hematology showing Annamycin’s synergistic activity against AML when used in combination with the Ara-C; based on this data we plan a potential Phase 1/2 trial with Annamycin in combination with Ara-C on AML in 2021

 

Immune/Transcription Modulators - WP1066 Portfolio

 

●

Reported positive interim results in Emory University pediatric brain tumor Phase 1 clinical trial; DIPG patient showed an apparent response in first cohort
 

●

Advanced WP1066 for GBM in adults to fourth and final cohort in dose escalation trial at MD Anderson; notified physician sponsoring trial is leaving MD Anderson; pursuing IND transfer and continuation of research
 

●

Received "Rare Pediatric Disease" designation from FDA for WP1066; entitles Moleculin to receive a transferrable Priority Review Voucher upon New Drug Approval for any one of three different brain tumor indications

 

Infectious Disease and Metabolism/Glycosylation Inhibitors- WP1122, WP1096 and WP1097 Portfolio

 

●

Multiple positive pre-clinical in-vitro studies on WP122 in its potential ability to address COVID-19
 

●

Positive in vitro results demonstrating the antiviral activity of WP1096 and WP1097 in a range of infectious diseases including: SARS-CoV-2, HIV, Zika and Dengue Fever
 

●

Working to initiate a Phase 1a/1b clinical trial in COVID-19 or a physician-sponsored clinical trial for a cancer indication, or both in 2021

 

Anticipated 2021 Milestones

 

●

Potential for 8 clinical trials in 2021, including 3 to be conducted by Moleculin and 5 primarily externally funded and conducted trials; External funding will be relied upon to the extent it is available

 

 
 

 

Management Discussion

 

"We are extremely pleased by the progress we made over the past year despite headwinds from the global COVID-19 pandemic. 2020 proved to be a pivotal year for the Company as we progressed our clinical trials and expanded our product pipeline. Although we are still in the early months of 2021, we are excited to see this momentum build, as we have raised approximately $81 million in the first quarter, which will enable us to further pursue our pipeline with expanded pre-clinical and clinical activities, through at least 2023,” commented Walter Klemp, Chairman and CEO of Moleculin.

 

“We continue to see tremendous progress and promise across our three primary drug candidates, which have accounted for five Phase 1 clinical trials either completed or under way to date. Our lead candidate Annamycin, our “Next Generation Anthracycline” designed to avoid multidrug resistance mechanisms, received an independent assessment last year, which confirmed the absence of cardiotoxicity in patients treated in both our US and European open label and single arm Phase 1/2 clinical trials for acute myeloid leukemia. We were pleased to conclude our US Phase 1/2 clinical trial of Annamycin in AML, and following discussions with the FDA, will focus on establishing a recommended Phase 2 Dose and generating requested safety and efficacy data within our European trial in Poland. In our European trial, we are currently treating patients in the 5th cohort at 240 mg/m2. Dose limiting toxicities relating to liver function have now been noted at this level sufficient to establish an upper limit of dosing. We are planning to amend the protocol for this trial to allow exploration of an intermediate dose level between the 210 mg/m2 dose in the fourth cohort and the current 240 mg/m2 dose level, in order to establish the maximum tolerated dosage (MTD) and Recommended Phase 2 dose (RP2D), which may be the same. As soon as the RP2D is established, we intend to begin a Phase 2 expansion phase to assess the efficacy of Annamycin as a single agent. In addition, as a result of our preclinical research showing potential synergistic effect from combining Annamycin with Ara-C (a drug commonly used as a single agent and in combination chemotherapy for AML), we also intend to begin the Phase 1 portion of an AML trial using Annamycin in combination with Ara-C.

 

While we are pleased by our continued development of Annamycin in AML, we are also excited by the encouraging results observed in Annamycin’s ability to treat lung metastases. Sponsored research has demonstrated that Annamycin is capable of accumulating in the lungs in animal models at concentration levels up to 34-fold higher than doxorubicin, the current standard of care chemotherapy for a range of lung metastases. This research has also shown that Annamycin has activity in several different lung metastases, including sarcoma, colorectal cancer and triple negative breast cancer. Most recently, we announced that Annamycin demonstrated a potentially significant therapeutic benefit against metastatic osteosarcoma in a preclinical animal study. In this preclinical study, computerized tomography scans showed that animals treated with Annamycin exhibited significant suppression of tumor growth. Further, not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. As of day 130 in the trial, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. We have received both Investigational New Drug (“IND”) status, and Orphan Drug Designation (“ODD”) for Annamycin, allowing us to begin a Phase 1b/2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. To manage the upcoming Phase 1/2 Study in the US, we selected Catalyst Clinical Research as our contract research organization. Our efforts in progressing Annamycin in lung metastasis have also paved the way for a second European trial in 2021, as our license partner recently received a $1.5 million grant from Agencja Badań Medycznych in Poland to fund a Phase 1b/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases in Europe.

 

 
 

 

We also continued to drive the clinical development of WP1066, the lead molecule in Moleculin’s portfolio of immune stimulators and modulators of transcription. WP1066 is currently in two US physician-sponsored Phase 1/2 clinical trials, one at MD Anderson for the treatment of glioblastoma (“GBM”) in adults and the second at Emory University for the treatment of pediatric brain tumors. In our Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children being at conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, the first cohort of patients was treated with no adverse events related to treatment and the trial has progressed full enrollment of the second cohort at a dose level of 6mg/kg. Notably, within the first cohort, one patient with diffuse intrinsic pontine glioma (“DIPG”) showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size; we are particularly encouraged by this apparent response as approximately 200 clinical trials have been conducted in DIPG, and no drug to date has been able to show significant activity in this disease.

 

In our trial at MD Anderson, WP1066 is in the fourth and final cohort in the dose escalation phase. We were notified during the first quarter of 2021 that the physician sponsoring this trial is leaving MD Anderson. Although we cannot be assured that this trial will continue at MD Anderson after her departure, we have requested that MD Anderson have the IND for this trial transferred into our name to help ensure the potential continuation of this important research. While we are making arrangements to pursue this research in additional physician-sponsored trials, we expect that continued research on WP1066 in adult GBM will be temporarily delayed in 2021.

 

In addition to WP1066, we see meaningful opportunity in WP1220, which is an analog of WP1066, in treating cutaneous T-cell lymphoma (“CTCL”). The US market for CTCL had estimated sales of $40 million in 2020 and consisted of technologies that are as much as 40 years old. The data from our WP1220 Proof of Concept Trial for the treatment of CTCL, while limited in patient size, was promising; WP1220 demonstrated an objective response rate of 45%, with no adverse events and 55% stable disease, resulting in 100% clinical benefit. Given the tremendous market opportunity and these strong early indications of efficacy, we plan to seek a collaborative partner to support a Phase 2 clinical study of WP1220 in CTCL in 2021.

 

While we continue to drive the further development of our drugs that are showing meaningful activity in cancer indications, we believe our WP1122 portfolio holds tremendous opportunity for creating long-term shareholder value in the area of infectious disease. In 2020, WP1122 demonstrated its unique mechanism of action and in-vitro activity in numerous preclinical studies and independent research. We believe the preclinical work conducted and under way for WP1122 will support an IND application or its equivalent in other countries for either cancer-related or virus-related clinical trials (or both) during the first half of 2021. Although our initial preclinical focus for the WP1122 program was to help provide a treatment for the growing COVID-19 pandemic, we discovered that two other molecules within our portfolio of antimetabolites displayed significant in vitro antiviral activity against SARS-CoV-2 and other hard to treat viruses. Independent laboratory testing of our drug candidates, WP1096 and WP1097, not only showed significant antiviral activity against SARS-CoV-2, but also showed greater potential against HIV, Zika, and Dengue Fever. We caution that the above data is preclinical and there is no assurance that we will see similar results in our planned clinical trials.”

 

Mr. Klemp concluded, “Our strategy since founding Moleculin has been to deliver long term shareholder value through our ‘multiple shots on goal strategy’. Following our recent capital raise in the first quarter of 2021, we are now optimally positioned to deliver on this strategy, with cash runway through at least 2023, and the potential to see 8 clinical trials this year on our drug candidates."

 

 
 

 

Financial Results for the Year Ended December 31, 2020

 

Research and development (“R&D”) expense was $12.8 million and $11.0 million for the years ended December 31, 2020 and 2019, respectively. The increase in R&D of $1.8 million was primarily driven by increased clinical trial activity (3 drugs in 4 clinical trials in 2019, versus 3 drugs in 5 clinical trials in 2020), increased costs related to sponsored research agreements, costs related to manufacturing of additional drug product, and two additional employees in R&D headcount.

 

General and administrative (“G&A”) expense was $6.8 million and $6.3 million for the years ended December 31, 2020 and 2019, respectively. The increase in G&A of $0.5 million was mainly attributable to increased payroll related costs for an additional finance staff, increased stock-based compensation expense, and increased costs for officer's liability insurance being partially offset by reduced travel expenses due to the COVID-19 pandemic.

 

Net loss for the year ended December 31, 2020 was $17.4 million, which included non-cash gains of $2.3 million on warrants in 2020 as compared to $4.1 million in the prior year and approximately $1.7 million of stock-based compensation expense in 2020 as compared to $1.5 million in 2019.

 

Liquidity and Capital Resources

 

We believe that our cash resources as of December 31, 2020, along with the additional funding received subsequent to year-end, will be sufficient to meet our projected operating requirements, based on our current use of cash, through at least the year 2023. Such projections are subject to changes in our internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity.

 

 
 

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

 

For more information about the Company, please visit http://www.moleculin.com.

 

Forward-Looking Statements

 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, our expected cash runway; establishing a recommended Phase 2 Dose for Annamycin in 2021; the timing of the commencement and progress of the clinical trials conducted by Moleculin and by third parties; the ability of Moleculin to find a collaborative partner to support a Phase 2 clinical study of WP1220 in CTCL in 2021; and the ability to file for W1122 an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

Contacts

James Salierno / Carol Ruth

The Ruth Group

973-255-8361 / 917-859-0214

jsalierno@theruthgroup.com

cruth@theruthgroup.com

-- Financial Tables Follow--

 

 
 

 

 

Moleculin Biotech, Inc.

                

Unaudited Condensed Consolidated Balance Sheets

                

(in thousands)

  

December 31, 2020

    

December 31, 2019

  

Current assets:

                

Cash and cash equivalents

  

$

15,173

    

$

10,735

  

Prepaid expenses and other current assets

    

2,025

      

2,749

  

Total current assets

    

17,198

      

13,484

  

Furniture and equipment, net

    

483

      

316

  

Intangible assets

    

11,148

      

11,148

  

Operating lease right-of-use asset

    

202

      

287

  

Total assets

  

$

29,031

    

$

25,235

  
                 

Current liabilities:

                

Accounts payable and accrued expenses and other current liabilities

  

$

2,920

    

$

3,570

  

Total current liabilities

    

2,920

      

3,570

  

Operating lease liability - long-term, net of current portion

    

159

      

276

  

Warrant liability - long term

    

8,192

      

5,818

  

Total liabilities

    

11,271

      

9,664

  

Total stockholders' equity

    

17,760

      

15,571

  

Total liabilities and stockholders' equity

  

$

29,031

    

$

25,235

  

 

Unaudited Condensed Consolidated Statements of Operations

                                
         

Year Ended December 31,

  

(in thousands, except share and per share amounts)

              

2020

    

2019

  

Revenues

                  

$

—

    

$

—

  

Operating expenses:

                                

Research and development

                    

12,757

      

11,013

  

General and administrative and depreciation

                    

6,985

      

6,511

  

Total operating expenses

                    

19,742

      

17,524

  

Loss from operations

                    

(19,742

)

    

(17,524

)

Other income:

                                

Gain from change in fair value of warrant liability

                    

2,346

      

4,062

  

Other income, net

                    

28

      

15

  

Interest income, net

                    

13

      

13

  

Net loss before taxes

                  

$

(17,355

)

  

$

(13,434

)

Income tax benefit

                    

—

      

229

  

Net loss

                  

$

(17,355

)

  

$

(13,205

)

Net loss per common share - basic and diluted

                  

$

(1.76

)

  

$

(1.95

)

Weighted average common shares outstanding - basic and diluted

                    

9,845,685

      

6,786,901

  

 

 

 
 EX-101.SCH 3 mbrx-20210324.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mbrx-20210324_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mbrx-20210324_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Entity, Ex Transition Period Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 mbrx-20210324_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 moleculin-logo_horizresizedf.jpg begin 644 moleculin-logo_horizresizedf.jpg M_]C_X 02D9)1@ ! 0 2 !( #_X0"L17AI9@ 34T *@ @ !0$2 , M ! $ $: 4 ! 2@$; 4 ! 4@$Q ( @ 6H=I M 0 ! >@ !( 0 $@ !061O8F4@4&AO=&]S:&]P M($-3-2XQ($UA8VEN=&]S: Z ! , ! $ * " 0 ! XZ # M 0 ! / #_X0M":'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI. M5&-Z:V,Y9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O M(B!X.GAM<'1K/2)835 @0V]R92 V+C N,"(^(#QR9&8Z4D1&('AM;&YS.G)D M9CTB:'1T<#HO+W=W=RYW,RYO7!E+U)E&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O M(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C(Q.4-#0C)#03DX,S$Q13(X M-S,X1#$T03#IX;7!M971A/B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_ M>'!A8VME="!E;F0](GH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? M 0 # 0$! 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$ M! ! G< 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(RKR\_3U]O?X^?K_VP!# $! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" M @,# P,# P,# P/_VP!# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_W0 $ !W_V@ , M P$ A$#$0 _ /[^* "@#XY_:H_;U_9?_8WL+=_C9\1[33O$NHVSW>A_#GPY M:S^*?B1KUNG'VJP\(Z5YE]::86!7[??&ST]&&&G%??\ !/ACQIX@591X;P%">"P M'(]+%?0]RUTG]1SO%1K6=O:82E*-^E^3$J27FHR?DSS*7TT,-&HO;Y11E!RB MFH8FK&5FUS-<^%46TKM*4H)M6Z_6/]EG_ (+0_L;?M+:II7A#4M>U?X&? M$/6+F&PTOPO\75TO3-'US4[B6*"VTWPW\0M)O]2\$ZGJ-Y-.J6]G/=V>H3L< M);D@BOPKC;Z//B%P;0GCX4:>9933BY3JX7FE*$4FW*I0G&->$8I-RG[.5-=9 MJZO^]<$_2!\.>-:T,%1Q,L%F52:A&GB>6$9S;@E&G7C*="1_G_.:_"GH?MPM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % '__T/[^* /B;]LOXD_M/:3X7MOAC^QO\-5\8?'/QS!/'%X^ M\4RV6C_"KX)^'L2Q3^-_%^M:N&M=8U^65&BT?1;.#4+F6<&YN+E'D34OQJ\$_\&^WBGXAZ MWJ_Q"_:\_:O\0^)O'/B^[BUGQ<+]%VKG^)JYOXB9S6Q.9XJG!U8X>$'^]2?-*5? M$1J.KRW4:;6'HJ"3Y81BU"/VKX=_X(.?\$^]$M8;?4O#7Q;\6RQHJO=Z[\:O M'-A),P W.UKX0OO#&G(6/9(E4>G3'YUBOI-^*V(J.=+$8&@F]H8+#R2^=6%2 M7WM_Y?HV"^CAX583#QP\L)BJJBK7GB\2F_\ P"I!:^21K:K_ ,$+/^"=^H0O M%9_#WXD:$[K@7&D_'+XJO+&3_$L6L>)M7M'(/.'C8?AUPH_26\6J'/#'Q'\-S(6#-87=UH5KX%\326LF,$S7-V!Q MN1P,']!R/Z7'$5"<(<1Y7A,326\\/4JX>I?^9*;K4D_\-./DUN?G.;_1(X2G MS5N&\PQ>$Q3J*25:-/$0:NGR2:C1K2C=:*5:5FE=22Y3WG]B9/V^/V$?$>C? ML]_M::'<_&S]F;5KY-"^&W[17@36]2^(#?![4KBZ%OHWA_XB6VI6=E\0-*^% MNKO+'#;W=[:WMOX6G94EU!M+8'3_ );Q&GX7>)>$J<5\#5%EG&%.//B,!6IQ MH+%Q4;SJ8>4)2H2Q,+-RA&5-XI*\**KJU;[#P[H^)GAU6APOQM&6:<*SJ..' MQ]*I.O4P\IU&H4\1"<57CAVG%1F_;+"_#4K/#I3I?N@#FOYL/Z$"@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * "@ H * /__1_OXH ^7OBW^VM^R1 M\";HV'Q<_:*^$'@?5T#DZ#J_CC17\28CX?9X;T^YOM==E)Q@6^><#>')^RSW-,!A*SBVH5:].,V MENU!RYFM5LGNO(^0]1_X+:?\$WM/NYK2/XZZOJGDN8VNM$^#WQEU6P8^L5]: M^!7MYUP>J,0?6OOZ7T$V=P<\'GF"ARMIJNY89IIV=XXB-)K;=JW;2U_OGPGX MV\'>/='@\0>!_%?AOQCH-TJ/;:WX5US3/$.DSHZ[T:+4=)NKRT=67D?/7Y=C ML9)-'Z?A<9A,=16(P56G6P\E=2A)2BT^J<6T M_O?^?45QG0(0#U&>WX>G;@T[L Z#Z#I]/SI ?@G^V%_P7&TK]DO]I#XG?L]W M/[-^I>.)OAQ>>&K1_%<'Q2T[P]!JQ\1>"O#?C%771[GP?J4MF+1/$(@.9Y Y MB+Y ;:O]/^'_ -&O&<><(8+BNEF]+#0QD:C5)X:+V\0>'?%G]MVD6LP M7-MH6A)9FPUKP]<6TL.V4@&*0L/,"CXCQ<\&\=X4_4:E7&1QV&QOM8\\:3I< ME2ER-P:3P]\+O OB;QSJEM M%((I[Z#P[I5SJ*Z;:R%) MYJ<\*6\/RM^]E7@]#^8\-Y'B^)L_P7#V M]R3%Y[C;_5,'AZE::6[C3BY-+S=K+S:/ MYS)/^#E'2X+>8S?L>ZLMW;6DTUQ;)\;](D6.>VMWFN(!,/A_O=$>-E#[,L!G M;VK^MX_0]Q/B!\/? GCP6!TH>-O!OA?Q< M-+-R+TZ:/$FAV&M?8#>""V%T;/[;Y?F"-/,V[MJYP/X]S3!?V;F6(R[FYW0K MU*?-:W-R3E&]KNU[7MTO\W_8V"Q/US!T<7;E]K2C.V]N:*E:_6U['9UP'2-= MMJ,V,[59L>N!G'XXIK5V!Z*Y^)7[%_\ P61L_P!K[]IO3_V<8/V>[_P#)>Z9 M\1M1;QA2.S]OZ)\0O "OP#P8^ M,*F:T\5#GP\526'E3?[]-IN;J27NVV2=_+K^!< ^.V%X\XSJ\'T,MK8:=&.( M;JRK0G%O#SC!J,(QYM6[WDXVTY5--N/[;U_.I^^A0 4 % !0 4 (3@$^@)_* MFM78#\._B]_P6#KB[A_L4_$ VJW4GVC[,,2IYI\O^C\@^CW5SWPXCXA1S:%*G M++L5BG0>'E*2^K/$_N_:*JHOVGU?XFER\WPOE7-_/6?>/='(O$C_ (AU/*JE M2O+'8:A&NL1!0Y<0L->I*#I\Z=-XBW)%34K0?M(\T_9Y/[;'_!;;2/V-_P!H MSQU^S]>?L]W7CR?P5IWA/43XGA^*VD^&5U%?%/AJQ\0K$-%N_">I7%N]D+SR MCB:7S-H;"[@*Z/#CZ..,\0N$\-Q51S6&&AB*E6/LWAIU.7V9[:*\>;] MTK.X^UVEM=;/+^T6\$^S=NV>=$DNW=A<[=^,XYK^:9QY9N/9M'](1?-%2[HL MU(PH * /_]+^\'XE>!-'^*'P]\;?#?Q#?:YIV@>//"VN>$-;O?#.M7?ASQ!; MZ3XAT^?2]1?1O$&GLE_HNI&TN7$5U R30.0\;*X!'HY3F5?)\TP^;86-.>*P MU:%6"J0C4IN5.2E'GIR3C.-TKQDG&2TDFG9\F/P=+,,%5P%=SC0K4Y0DXR<9 M*,E9\LEK%V>C5FGJFGJ?FCH'_!$7_@FSX>B>.'X$:I?O(NV>?5?BW\7[A[@G MJ\RQ^-H+9Y"QSN" YK]CQ?TC_&'&-2J9K&*3TY<+A%;T_#N% MDYTLI;[IT,/Q+_P $+O\ @G?KMO+!IGP[^(7@N64/ MB[\+?&GXFEX6;^..S\2>(/$>DN0>=KV[+[$<5T87Z2WBUAYJ5;&X7$)=*F#P MNO\ V]"E3G]TK^:W>53Z.'A*Z$L/A\!B*,97^#&8MVOVYZTTM]K6_3\Y_CC_ M ,&YU[:6-UJ'[-/[1%W=W,-O.8/!WQJTBVM/MS(H:&WB^('P[LM/BL6D"E"] MWX>O,ZT:?&.40]FY*]7!R;Y>[]AB)3YN]H8BE_E^0\1_1# MPT<+;@W-Z].K&ERJ&)LN>2M9NMAHTDFTFFYT*VK3MHT_Q \<_";]MS_@G!\2 M+:XU73_B?^SWXIN;Z.'1?&7@K6I],\+>-3:37301Z1XL\+SS>!O'PEBB=SIN MI)/>B%BT]A&I('])Y;GOAGXQ9.X4IX/-<)&#9RI5?W^'LVDZM M&4:?,K1K29_,V:9%XN^">;^W2Q>";G",:E&7+3K1A4J.G"-2FGAZ[DE)^RJP ME6Y9ZX>-]/V>_8B_X.!-;LKO2O 7[;.D1:SHS+':Q_'7P/H?V;7=*$<,2"Z^ M(7P\T>)K;7K5GW//J/AZ&"XC')THH&E'\\^)7T5*+A4S3PXJ.%>]_J5:=X2N MWI0Q$VG!I64:>((T4E"FV\92@^9MZ5>()+:_TS4K*6:VN[:53PRMP<@@$$#^)\PR_'95C:N6YE2J4, M?0FX5*=2+A.$XNSC*,DG%KJF?V]@\9A,QPE/'8"K3K8*M!3A4A)2A.,E=2C) M-IIK5--_Y]*>A^AKC.D_AQ_X* 65EJ'_ 6P\266HVT5Y87?[1?[(UG?VLT: MR176GWVG?L^6.HVLD; K)'=V%S+$P((*N:_TG\+JE2E]&VC4I2<:DGBH*=+^T\J=G_U[RU?DW\CVK]@*6?]B#_@ MLMXZ^ 5\\FF^%_&'C?XM? B"!+ATM)M%\33+\6_@??RVLACB+KH]EI]G&0"5 MGU.15)#'/S7BFH^)'T><)Q53]_&X;#83&-M>]ST_]CQJ4E=ZU'.HU=7C23>J M5OM/"ZE#PY^D+C^%E!4(_A[^R5X7^#EGJ"VFK_'WXA:=9ZK$+MH9E^'GPU6+QUXKN&MX@ M9[BRN=;M-'T^=6;\>5L_G!RP^5824HZ73Q&(_<45=Z M*2C*K5B][T[K:Z_7OI0<4TLEX"IY$IPCB'H+V]>48P3G47NTZ M4XJT6JMI/7EG_-_^V?\ F7X"_ #]A/1]6TO^SO&'Q"_9N^*WQG\9":T^R7R MZI\3_'UCXCT?2[^-V:<3^&?"=S8Z>%%_"^AVT6I>,?'/B(_#S2+U/#_A72);FTBN;I+*VDGN+B MXFMK&QMD::YGBB4L/\_4HPBDY3E&*;7Y*W7_!Q#XBN'U+Q3X>_8@\5ZA\*-&U6'3M3\7WOQ(U M2-[+<]NLD>J:KHOPIUSX=Z-JH^TKBUGUT89E4N-P)_>:?T3\)%4\#C.)SLM-?P"K]*C%SA7S3 <-8JKPUA\1"E/ M$.O)63<.:3<,+4PT''G^&6*6R4I0OI^PG[$W_!03X%_MV^#]=U7X9S:QX;\: M>$HX/^$X^%WC%=/M_&'AN&^:Y@T_6(6TN\O](\0^&-2N+2:.#4+&>6)9HG@G M6"X5XE_ /$;PMXF\,\PI8?.E3JX"O?V.)I.3HU&DG*'O1C.%2*E%RIU(J5FI MQYH2C)_OGA_XE\-^)&63QV1RG#$4I.-6A5Y55IVE**D^24X2A)Q?+*,Y+1QE MRSC*$?Y;?^"*W_*3K0O^Q;_:1_\ :-?VG](K_DRJ_P"OV7?^D3/XX^CQ_P G MIQOIF?\ Z?IG[H?MH?\ !:SX/_LS?$G4_@?\+_ASXB_:&^+N@ZM#X=\2:?H. MK)X>\(>'_%%P;7;X2_MN#2/$NO>*?%EL+E5N;+1M*O5M9C]GEE2Y5X5_FSP\ M^CKQ!QED\.)'ZM-U*>K.DN:]7DK3YE[\4X6;_ M *'\0?I"\.\&YM/AK*,+7S;B6%>%&5*FW3IQJU.2U/VG).=2:4XN4[U6 M.!M,E^(.E^)?"OP_\;^#M)N6N$5K]M,N;2W219[AH;8/,GT'$OT6\YPF3RSK M@O,\/G5"-*4U3C!0JU%!M36'E2JXBA6DK-\BK1G*SA!2J6B_GN'OI09'6SU\ M/<;9=7R3&+$1I.I.HIT:7/352$\1[6&&K482;C#G="4$YPE*2@W./ZP_M>_M MD?!O]BWX3O\ %;XL:C>W$.H7G]C>"_"/AQ+.\\5^/?$YN[ZZG@L;&T1I9I5&T-^&(>>K(\BA%3C'GJU:EU2HT[J+G4 M:C*7Q-1C",93G-J,(ML_=>-.-\AX#R26>Y]4<<.G:$8V+-)^%>MZEJ-CH_BK2_B2;K5+] M=-F>*\739/$'P^\+_#_7-4T]8V-U:VNOL;9P5D==K,/Z1K?1-C*E/"X#B+#5 M,_I0A*=&6'M&/,DUS>SKU<1",KKDG/#+G5FD[I/^<Q5#AJO M5J0IXA5U)M4Y-7]^C2PTG9-SC#%3<+23ORS /BC\0W^&MMI&BWFC^$_$_A7Q):>'?%6O:QIWBVQ\42P1Z7JFA/ MX5EMKFVW%R\LQFI*33O:U[J_U+^Q3^UAHO[:/P&TGX[Z!X+USP#INK^)?&GAJ M/PYXAU/2=6U2WF\%>(KWPY=74MYHC2:E1HU'4IQG:E&JDE-1E>*DD[Q6NVEF_M>".+<)QQPY1XD MP5*I1P]:52*A-IRBZ&OVSIOV,9O@ M5X^N_$2?&_PW\$!XZ@\5^"XO#S:CXDN/#\,7B :7<72:Y_9UE%X@1Y8O*,Q\ MIE0,2N?TG ^ &;8WP[7B+',L)'!?V=5Q?L73K.IRTG43AS*#AS2=-I/FMJFV ME>WYWF7CGD>6F_#R]O_B+< M:)\'[N;5HO&5A#%HUM!%MSO9T6)%V87A?YU\-?";CGBW@RGQ M%DG$,LORQ3KQ5#GQ:Y71]Z;2I>XN:]^C;;W>I_17B+XK\$<(<6/A_.LF>-S6 MI"@_:*&'?-[9\E.+=5J3]Y./512O)QC9OUK]LW_@L=\/?V+?CK=_ ;Q!\#/' M'C2^L?"7@CQ0OB/0/%G@K1-&%KXS75%M+$VNNW-M=PR::-(?S7P8MA# \$#Q M/#SP SGQ%X:7$V"S'"X>E+$5J7LZE.O.=Z*@Y2O3A)-2YU9;WTMJK^IXB>.W M#_AOG<M?C+XJU_5_AQX3\;:E8EDU"W^'TR> /% M5AJODR6MPL2WEY974ODEOLZQ_-7V?#/T5\=F6%Y.(,YPV!X@=)5'@Z<(8BM1 MC+X7B%[>G*G?FBVX0J12E;FYM'\+Q9]*3+LDJ1Q619/BL?PVZKI+&SE.A1K5 M(\W-#"R]A5C6:Y)_%.E=QM'F5VOU3_8;_;V^#7[>/P_UGQ;\-(]9\.>)O!U[ M8Z9\0/ASXI^P'Q)X3NM5AGN-&O?M6E75[I.N>'->AM)S8ZA:RF.5[>:&1(;F M":"/\2\2?##B+PQS6G@,Z]G5PF(BY4,12YO9U5%I3C:<8SA4IMI5*#QU"M*,E=2C M3J1E)-=4XIIG@\4Y0\_X:S#(XSE3EC,%6HJ2M>+J4Y04E>ZNFTU=-::I['^? M-\.?VU/VP/@7JJ2> _V@?C;X+O;)1!>Z!<^.?$.NZ1;7T+*M_IU_X.^(,WBS MPP)M-U""2WD1K ,CQLI(.0/]6,U\,_#SB?#6S'*LLQ%*3O&I&C3IR<7\,HUL M-[&HU*+4D_:---.VQ_DUA_&+Q,X/S9T\-F>8PE2@X.$ZM64>9VYN:EB_;QYJ M> =-\8Z'--#;2?%#X5Z:GA_Q= MIL._HFX&=*>.X"Q4Z M&(2;^K8J7/2E:[M#$1BI4V]$E5A."U&@U*48JOA MX\DU?D5YT)3E&HN9S;=*HJEK1AAIM7?]/?P8^.'PH_:&\ :+\4/@SXYT+X@> M!]>1_L6MZ%A-6T>THM7C.$EK&<&X25G%M-']IY!Q!DO%&54<\R#$ MT\5E=>"E"I!Z-/HT[2C);2A)1E%W4HIII=!\0_AQX"^+/A#6_ 'Q,\'^'?'? M@KQ':266M^&/%.DVFLZ-J-NZD?O[*]CDC$T1.Z*5-LL+@.C*P!'+E6;9GD>/ MIYID]>MALQHRYH5*4W"<6NJDK/U6J:T::T?7F&78#-L'4R[-*-+$8&K&TZ=2 M*G"2[.+NG_7R_CK_ ."H_P#P1SUC]E^RU?X]?LZC7/%WP"M6EO\ Q=X6O\ H#X)?2$H\8U: M?"W%_LJ'$TK1I5(I0I8M_P JBK1I8A]*<4J=?:E&G5Y:=7_/CQW^C8^',-/B M[@=5:F4TVY5J;;G4P\=^;F=YU*,?^?DFZE%:U'.DN>C\W_\ !,G_ (*:>._V M'_']OX4\776L>)_V=/%6L9\>^!T\V^N_"][>2A+SXA^ +,Y-MXELS^]U+3HM ML6OP*WR_V@(I)?K_ !H\%\L\1\K>999&G1XLHT_W-71*K%+2A7>EZ;VI5'K0 M=DW["ZA\?X#^/&9\!YK'AWB.)_"/BW1=.\1>&O$6C74=[I6MZ'J]I%>Z9J> MGW43-'/:WEI,KHP/0\X.17^9..P.,RS&U,PF8X2EC\!4A6P5:G&=.<&I0G"24HRC):.,DTTUNF?Q/?MY M_P#*;K7/^SD_V/?_ $1^SK7^C/AE_P HU4_^Q-F__O1/\Z..O^4K,1_V,LJ_ M](RP^H?^"\W@#6/@9^UQ\ /VOO!UHT-WXATG1-0-RD6V'_A9_P"SIXHL/%GA MY)+F-=T-UXC\-:A!"222T&EL!D*0?B/HPYG0XFX$S;P_Q\O9?WJOFF?H7TF,MGPYQMDOB%A81IX89=7\'_!C..*LQ@Z> M)K*ZU4J,G@L"FI62_P!IE.IK=N$D[/KP>*&/H>+'C/D_!F JJIE$(X>$TJOL MTXU8K&XQPG!.I*2PL*<$HN"YKIR6LETO_!QK:VUC\:OV=[&SACMK.S_9X^(% MI:6T*".*WM;?Q?ID-M!$@X2.&%%4#L!7']$6U;Q!J:HV4>2Z;X>:3"QQ]VTVG(.*^V^CIE6#H97G68QC_M M6,XFQ-.I+^Y0E2A"/R^M5GZR\CX[Z2V.Q>+S_(\IJ3_V"CDU&<8V5U.JJU24 M[N_7!T$E:WNR33OI_8U^SW\'OAUX)_9?^%7P'Y[2 M*ZTS6[#4_#-DFN2ZQ;S!X]4N/$4UY//>R3!WN9IW=RS,37^?_%&?YMFO%^-X MAQ5:I_:U3&U*OM$[2C)5&X\C5N50LE!1LHI)+1)']Y\.Y%E>4\,83A_!481R MJC@Z=)4VKIPY$FI7OS.6KDW=R;;;;=W_ !U?\$R;^\^"O_!6CP;X"\$W-Q'X M:NOBO^T#\"[ZT6:2==1\!6$/Q1BL+>ZED)FN/L=Q\,-%NA([,S26F\Y8DU_? M_C+3AQ)X#5LVS-)XY8'+\:GHK5Y?5>9I+176+KQLE9*5DDDD?P1X.TO]5_I MRR3*).&5_6,9AG#XN:DOK2BN:5Y>[]2P[3O=\CYKMMO)_P""4/B.]\)_MW:_ MXNT]=^H>&OA)^UUXBLH]H827FC^'+S5+9-IR#NN+5>.KC5@_S7]=?GK]@#]HSXF?!' M]I2/XY>$?@7??M/_ !,'@7Q7?KH9M/&FK:O8:SX\G\.ZAXI^)"/X'\'^.->C MU"*YO+N!YS9K"O\ ;#7*H-1Y^9^PBU&2BVO@O"/C+.\E\2<3G>'RNIG6:_5*LE[M6= M6$J[H3JU5*E1KU%[TIIV@HKV\ES1NHR^D/V_OBE^T]^WSXV^'7C;Q+^PE\3O MA;K7@OPYK?@_5+_PW\+OCUXFN_%N@ZSJVE:E:0:O=ZK\'_#L\*^'1:WL=J@\ MX%-4N/F0'!^.\*\FX+\+,NQN7X/BC XZAB:L*L(U,3@*4:52$)Q;C&.-JI^T MYH.3]W6E#>VGW7B]B^-O%''Y?C7PSC,%6PL)TZE2.'QU2K.E.=.7*I_4Z>?\%*?B=\5_%'AC]A;PK\3HO$NF:Y\/?V OAIJEYI'B[3M6 MT;Q+;^-_$E_XVL_$^HZUI>MPV>J6&LW"?";1TF6>&.<-$=WWC7K^#.2Y%@L9 MQ/C\E=&>%Q?%>)A&5*49TG0I>Q=*,)0O&4+8RJXN,G%IJW=>1X[YCG>*_P!5 M\ESN4XU%X'QD:D\_P TYWDI5))-_\ DUF!_P"PC%_^I58_G^^+'_*=1_\ L_;X9_\ H_X<5_4G#^GT87_V3.)_ M]+Q)_*O%G_*4N$_[*##_ /IC#%?]L#_E-OKG_9Y7[-'_ *,_9JK7@#_E&R'_ M &3V9?\ O3-/$'_E)JC_ -C? ?GE1>_X+6_\I.O%/_8O_LY_^DBUG]'+_DR\ M/^OV8_\ I,1?2-_Y//AO\&6_^GIE'_@O)G_AOKQ,58HW_"E/@K&CKP\;36GC MN$31L.4FA\S>C#E7 /:M_HMZ^&-*+V_M/&7\[?5G;T>S\F_EYWTMZSP_'L,1 M%1BV?@GP/ M^ROXT?PEX>MM/MHM.\/W'@/P#Z%JVD6]S!,BK(D\8<$-D MU_%GAMG>:UO&/)\VK5ZLLQQ.>T/:U')N53V]>,:JD[WDJD9RC)/1IM-6/[0\ M3LJRS#>#F=Y;1P]%9=APP\IT>6%N5>SE"+C:W*XIK5*_X8?\ M&X-S,WQD_:@B#E(;GX4?"V[D@3Y(#,GC[X@>6PB&5'E+=2*G]U6([U_2WTO8 M)9+DG64<;BTF][>PPOYV5_0_G#Z'-1U%F]1V3G0P\FEHKNOC'HNRNTNR/ZW: M_A,_N(__U/[^",_Y_7GN* /XB_\ @MG^P;K/[/7QZU7X]^"-"D;X)_'GQ#>: MZMQ8Q;K3P7\6-6,VH^+_ A>I#$L=A:>+[Y9M* MR?/I<:9/2OD^.J;O[U- MZ7@W_%H2?LZJ_DJTADECMM9T:Y<#$UKJE*,E*$U&<9)?ZR<%\8Y)QYP]0XDR&,E:<'*$HR?T+=VEK?6MQ97MM!>6=W!+:W5I M=0QW%M)_T; M<;7\3,#7X1H^SR',JU^:$;QP?!GP#9O9>#_ (:^$=&\(:#%*Q>ZFM-'LX[=K^^E8LT^I:I=6HUHN:3 82A"E35[OEA%15V]6W:[;U;;;U9_([^V_\ [XUZY_P M6/UGQWH?P;^+VN>"9/VB/V3M0C\8:)\*_B'K'A)]-T>W^ AUG4U\5:9X8NO# M?]FZ.=*N1=SF[$5J;>7S67RWQ_=WASQ/PUAOH]4\IQ.8Y?2S-91FL72GBL/" MKS3>/Y(>RE557GGSPY(J%Y5.ZO_#/&?!G%>)^DG6X@P^78V>3RS'+6JT: M%:5)QIT\O=2?M53=)1A[*HI-S34H.-KM)_N1_P %H_V<]5_:#_8A\5R^$_#> MJ^*?'WP@\4^'OBMX3T7P_IVJ:MXBU6WTVXN/#OC72-%TK1K:\U'5K_4/ GB/ M4/)M8HI'GGBC"J6VX_FWZ//%U'A/Q)P[QU:%#*L?1GA:LZCC&G'G2G1G.4W& M,(QQ%.DY3!HO'?@?Q+X&DU+Q+\1]1>;Q)J6D6?BS1-%U#4%T+POX5A@:>!#"&UB1"Y?< M!^X?2C\0\GS'AK \-9!C,+BOK6*=:LZ%:G7Y:>'C:E&_#KX4_%'XA6=A\"_'^GWUYX!^&_CGQO M9V.H7?C"QFM+"^N_"?A[6K>QO;J&-GCBF9'=5) (&1S?13S_ "#)LAS.&<8_ M X.I/,L-**KXBA0S:74]CZ47#7$.?YEE$+GQ#\6OAA^S_X!^'?Q#^&30II7BOQ5X''AG3-0MCHEIJDNFFX\5^! M]8NK^.72IY+>>YLM1N5A;[7##!-X7@MXOY-P=Q3G'#G$>(5'(<;F56O0Q&LZ M5*NIRB^?EYK4JT%"U2*DHSITW)>SE*-^'\KXBX:H*IQ)@L)3HU M*3]RK5H-1=H.4H+GHR<_WO!?A&T\!>%?'^N:!\3-(CF71M/_ +'\/:SXQ^&$GPY_X2/5/$FF M6EM!]I@L[J*WU2=/,\RT$A2/ZC.OH]\ 9]Q15XHP7$.%H\*XC$.M4H0JX64E MSRYJD*.(^L.E&G)N7+*<7*E'1QJN*O$G)N&J/#&8<-8ROQE2PWLZ> M(='%1H.48RC3G7HNA[;G24/:0@^6I)MJ=)-J'H__ 1E_P""//$GC+Q];74?B7XG>(/#\V+SPK8P:5J MM_!96][%;ZA=7>JW,KV]O##;F?R_I"^+W#>-X?CX=\&5J>(HRJ4_K%2B^:A3 MI4&O98:G/:J^:-.4Y0(:OB1QS2=+,)0FZ$*L M6JTJM?WJN(E%R;I1M.I&%.I"-7FJUKQIPY(/Y._X)(?L_?%S1/\ @H597WQ$ M^"GQ=\+>"-2\'_M&Z5?ZWXN^%?Q"\*^')+;Q'9FVM;237O$/AC3-'$FK6DCB M!//W3#[H)&!]IX\<5\/XSPFCA\JS++Z^9T\1E\E"EBL/5J)TXOF?LZ=24[0E M;F?+HSYOP+X1XCR[Q7Q>89KEV.P^6589A:=7#UJ4&JM6+IKFJ0C%\\$Y))NR MTERR:3XWPG\,OVK?^",?[9-[\0[?X'>*_BW\++"Q\8^!=&\2:3IGB.]\,?$G MX1^(+G1;K2 OC'PIX>U^V\%>/=(C\.:4US:ZI:1!;ZTG6-9K6>.[7U,PSS@; MZ0WA[#*JN:8?+\]E.C7G3G*G&=#%P513_=5JD'6H3=6KRRI3D^2<'+EJ0E2E M\]E?#WB!]'[Q#KYSA\KKYKP\X5J:J0C.I*OAI>S=.U2A1Y:->/L:*G"K3A#G MA/EE.%15*?TSXS_X*"_\%1OV]?B[X3\-_L6?#3XI?LZ>%HK&31Y3#H5IK&AB M_P!4OK?[3XY^*GQ*^(7PL_X1?2-%\.P1*8+#2R;PP&?8M]<30PP?&9=X6>"7 MAED-?&>(N.P.<8YS4[*I*,^6*=J&%P^'Q2JRG4=TZE9*FI+\3 M_&[Q&SVAA> ,LQ63Y2X\O-6I6:G>5ZN)JU\-*BJ*CRN-.A>MI*SFYGPV$&I^)=)\21WL\^F6B)+/8ZO<_8XFG@AMI?B?H]>+>1\,9SF'#N M=2AE^0YEBO;X:3+ MLAP>?Y-&6-XARO#2IUHJ*]OBJ-E*7L^3D3J<\7[D4KPJU/914^2+_-+Q[_P4 M7_; ^+/['7@#]A;PU^SS\7M&^)/AO3O ?@KQ5\2O"^D?%Y/'GB?P[\-[O2I_ M#VG:1X4\/>"M*\2^%?$&N'0[6#69Y+YD:%94B3;M2PU2>#=&G/$*2FYU:E>=*K3I\\I44H-\W*Y-."4_P JSKQ6 M\4,VX"H^'^79'F5+B'#0HTZV*A3QO/5AA^22]E"E0A5A4JN'+6O.RBY*'/SM MP^NM=_X)9_M5>)?^"5NH^%_%MQXJ\7_M,WGQVT?]I2#X:>)O'-_XH\0:7X7T MKP7>?#=?AG8:MXB\0:QI<7C*?P5JEUJ\EA'?K9'6)VM%GW?OC\%@_&O@C+_& MZ&89;##X;@R.62R]XBE0C2A.I*JL1]9E"G3C)TE7C"DING[3V$5-PO[A^@9O MX+<8Y]X*O(TR[^&^HO/X6O\ 78'O6N9C:26+/!GPR^(NN?#2VO M_$/B_P +^(-4NM#\:6'AFY\*R^%/"UAK,5D]RE]);6<6G21R3N8'F?ZC'<4^ M'5;P5Q64<+YC@X8+^P<31P]*OB<-#$M4Z=6$8SHNJJOM:LH2FH\BE-U8N,8J M2@OE<)P3XIT_'+ \0\68&K5K?VSAZ]:KAJ.(J89<\H\TH573E3C3I1<8-2J) MPC1=^;2I4]F_:O\ @=\;-8_X+':YXYTCX,?&'5?!1_:Z_9TUA/&.E_"?XBZG MX1DT?3I/V?3J>LQ^++#PQ<>&FTC2QH]U]JNOM?D6WV>7S&7RWV_.<#<3\-X? MZ/<,KQ&8Y=3S+^P2'LI555YY\\.2/)S2YH\J?,C[+CGA M'BC%_2&I9UA,/#)T#X!*GB/PA\*?B)XK\/ROI5FC:I'%K MGAWPUJFDR2Z:K#ST$VZ+HP!XK/P XFX;RWPCA@,RS'+\-C76Q_[NMBL/2J>^ MDH/DJ58SM)JT7RV?Y9^/W"G$^:>*U+-I MTYJ\(M2:O=[14I7BJW_!;3X&?&WX@_MS>(M<\"?!KXO>--!?X/\ P9M(]>\' M_"GXC>+="EO;"'QC]NL8]:\,^&-8TMKZR%S%YT/FB2(2+N R,[?1MXHX:R?P MXIX;-!PZYZ6'KU8&DN6_-H])6_J*_;0T76-?_8>_ M:?\ #^AZ3JFLZ[K'[,WQ9TG2=$TC3;[5=9U/5+[X;ZQ:6>FZ;I.G6]UJ6H:C M=W4BQQ6\,4DTLC!45F(!_BWPYQ.'PGB3DF,Q52%/"T\YPDYSG*,(1C'$0^ M._ASXX\$66IWEKXW\97-U::9=^+O#^B0ZC))%+ !A7]._2JX M@R'.\FRB.3X[!8NI#&XJ4HT,10KN*='#J+DJ-2IRIM22,E^C3LXR5G& M24DTTFOY!/VW/^"$'QT^$^LZQXS_ &7(=0^._P +Y[F>\@\))/8P_&7PE:-\ MXL;K3[N73]*^)%I;%@J7MA+;:I(@ ELKF;?-*3V:=D[-:]+_J MM_P1P_;"_$7B:S/P=^/.JZ%\//&VDKK=C=6ND>)]0NAIGP M[^(-M8VTUQ,+W2-:NX]*OW0 2:1?EY24T^$+^$_2'\-Z7&W!E;-<%0FN(,KI MSQ%*?LY1U6FXQ]ZO)O\ I7Z-/'N;<%\4TLBSFI;A M[,)PH.+J0E&-63Y:%51CS3YHRY:$M5'V,XRE:.'1_>&#FO\ ,8_TS# _S_GG M% !0 FT$YY_[Z('Y!A_*G=@& >/YISDXS M1?^^CC\MP'Z4[L!-H]_P9@/RW#^5%W_ M %8!2 3GG\&('Y!A_*BX 5!]?P8C] R_Y_4NP%_S_GI2 0 #U_$D_P V;'^? MP=V M(#_UO[^* "@ QGK]: ,#7?"OAGQ1 +;Q+X>T/Q#;*"!;ZYI&G:Q" &KD7?AWP%X+T"ZSG[3HOA30-*N,CH?/L+""7/X__ %MZ^:9EBH>S MQ.(KU(=I5)R7W.37]?=G2P6#HRYJ-*G"7>,8I_@E_7X]O7 =(4 % !0 4 % B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$! end XML 8 mbrx20210312b_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2021-03-24 2021-03-24 false 0001659617 8-K 2021-03-24 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive Houston TX 77007 713 300-5160 false false false false true true Common Stock, par value $.001 per share MBRX NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information
Mar. 24, 2021
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Document, Type 8-K
Document, Period End Date Mar. 24, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period true
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20210324/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx20210312b_8k.htm ex_233629.htm mbrx-20210324.xsd mbrx-20210324_def.xml mbrx-20210324_lab.xml mbrx-20210324_pre.xml moleculin-logo_horizresizedf.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mbrx20210312b_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "mbrx-20210324_def.xml" ] }, "inline": { "local": [ "mbrx20210312b_8k.htm" ] }, "labelLink": { "local": [ "mbrx-20210324_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mbrx-20210324_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mbrx-20210324.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20210324", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20210312b_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.mbrx.com/20210324/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20210312b_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity, Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mbrx.com/20210324/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001437749-21-006941-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-006941-xbrl.zip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�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

Z2W-\?KK>/!VN MZ166XH,8\RGM)G'1(OVL'D6(4;$7OUM-'&GY9*BR[M@173TV -RZ2C2I#-[* M"S20G9UPV)I/6,RBPG)"'R].5B'OZN[J&C9(CR3\I@6T(2HQ7 3.H4]^3SSH MG&>FZ(1]@DW1)X-D/L%U[)N(_=4A^('+]FM:-X=7AO:X!AMO8SY#5QM>5]7[ M<8XPI?[M!^C))SK^)/.WUMV[][2\HA+5">6C[ZT8"H3,LM/5)?3S,1X9(2S@A%O*->E<>>MZ1S[E:3,TX07Q7C$NVUWNCVYW/*M8.M93U%9&O04 M-B[JI4K\:IY:^#F/S&W!K;PP:\)\QW%,G5CQMPKR%*/;JXK^A3^66UPZ3H0H MSIW*DF]+'J8.9S)&6OTZZ1N?"U>-/E*'WXI*S95&UXKO?"'X>2E/IX__&#IZ MUA H1S$\93.RI_M/R$;-3NM'Q"URU$*]*VM\"R,"1LYRNNJSF#30GG>#Q)_R M@S^XZ0NP@L]:CVM-AC#&[V%94>>@[2CY@-APBH2^HXV1@67+M:$61VIPR*HA M:\S7A^*=UF3Y-[6>^RNE2K538R=@=:K:Z62K'Z_)4+6+V1P^ON,X.X/S48]H MG>>MBO4^=\53@HXFF<.DUG4&,1TJM_1 MS$YI4=*.4Q7),(;F?EHXB>U((7<@3893XI.X()R,T#0G;V*GX0X;I0ZA&F MV#:GK)+JJ,2VQB]-;-R%7^MJL_D0HN%=D#H7:U.USX:]@318JM^.#I=_]/,* M)J+/]W5$ -H.-.H^J_^V)QTZC]^<,B[ET4,I5'D:H+Y-?M0E;+\(;:DUY'KA M[9O@89HIHS$8!4G*$3++@C_]:6!P+%F>[FV[$9/XZR3O)+9E8<'(NV<;0N3: MJBS0+5G]5C'511K_>B0P63TKKL]T5[;Y)@(T2/#T>CJ*"A@H)#_EEA7BRQ5_ M!]/?'7@)U87(.7'X.Z6^R@@7:V#P^$]:V_-E=0^:_M+75452HV.@XFXUL>MXP&GB>*9I\S/#V_P"R( M/3-\+^C.L1(0.&"7J\U4O; MUR63ZW\4&]3*4%[,JF?"&CA&@"Q^/CWC_2E" M*B>)9.1[<2Y%S6]Q'0O9SD_U\79SCJ'",.$#&1J)):_+I81#@KD4VK^^8*@O M^X5J6T^7"+OF/H(6XWW=H_@X:ZC/4#X-VF, MD!F.R"C<0^;TRW7".\PALE>1 #'M'RVCJ*RV*XSPHHI8>0HC.UZ M!6--M"LYE#CZD#0>]Y-W[H9;W>?ZL2VE,*V@KWI)OXK=;IDL"NA^XLKPZ4JO M/&SM94UW%A%?"R1Q)\^86C^5$.\IM6G:-M[P+!MO3N,S-Q19D QESQ%ZV>=G M&A&?EI;'_V)_;XF[57W$:4O#/*[*KABF&>I&F:=.T@!G7,F,Q+/['(-[7L#C M6YT"EUL>;\?-\U >B58=B^RLHS@H82X$30'#EL1)# ?9K2U$10-N+9+63F%N M9]U LJCE@4P[**8O<2,KO<3Z3HY+>D/+\=&\41"S'#NK:KO7Z49*!QG[]90* M I2IF7O!F[/M(:Q3/1U1R?6RZ"0;(P(RLK,,%>%159;TS8'UOJV%?RG<;*D8 M8*..(\_3 "X"$Z@%9(=)PM'L:&G"_"4MKC5^+F)SC-=5]*( 'SF6 AH"FN.H MG$,B]55QRVO2I05Y! +!T_/:M4>P3VYQ(M+@@9F6YVHQ[<#+?H=<+,-FI7M3 M.U@SGXQTWO YTR#)_K["767N3OFT%='WQ@K9!C1 V(H#[+4OU[G!@=VC)#4[ M. 11GI@+^6Q17R_148<1_3"[)-XFH6YL&N<5#IE%MK9K"=:%&79H\9_$@JP+ M$>*#U3:!6R8=!RWLRG?G>@.F2UZO9WV*)V(X/1KF:+OF(' M6<@[%&%+$(OB2U_BP/JP?R+W]^0FDGV&8H=Y>[_6QD%^S+-;,LJ4,V5#^5QJ MUGUR?,IQQ3@;Q!T)D\L;W;:J+#!5)IE[2GRA5)Z'&=V0^\VHL?=FH^$W">1=M_.E,TTF2:&IJOFE!SOMM M/<6HNUC=GMR[6%ML5Q9[ FH[3X"N2?(W^E8-$JRLG2*AV1"W'S.ZFEC-2.EBG]4V QOH\:DJ+>.R7S99,A MU->*Y,55$@T@AKFV]I8&6#MR^QFS]7NU*"&#CQ41!B-4>@J0'$ 3ETC_(PH MUL'/L\..6$KR^(DQ,1137Z]@LN&Q-[-0>\-!',+VB:RE]Y,J+\D]K\=@MPR+ M>NLH9#8(=*1!HN=Y1"0XK/#H2."/JF8A 5C^IY4%]676KWMR-2RRXY=RGU8= M9K98I(R<8X14SF+&L M*6ZH9.&D>Z=_#7[P%44&#N"@[!2#GO[+9ECWECS\-OJ" MOKTF0K-S,@B1REW!5K!N_"&7U^'7Z%T3MBWGZ%(]=F^YE4"1ZC67E[G0DW,,1*38]C[=SO"-4E\&0'S'?GPX*F? M.YVM+M&=LS^]MS]A7G1V#O+:HDVK5/$Y]%_Y;A/XGWX&Q;&9)X2NCV*#((FW M"NM'/!0RVT=<+G::YTPE"$Z#@Q:-5?^$LPIG/$-9^.$P[GHJ =A;ZOZMJMP4 MB1ZSM/R+NNH0B$0EZ:P1#1 1Y_U^1&DKH -5$1.OA(IZ.HAQVXP4\+BRD::+2Y"G9UE%C:^5OF,)[DBO=E!% 0V2/1M; M/JIX=#\2HV?S3 _4K=RWN3':KJW0\".'V)MK6_ SE>J'.Y$<<93&*>(W+5EX MRZP*) B<0:*CZLK(\$1II=S4@ 1Y<]^JU!;I&:2NECJRU;[Y+$+V)"/\*G4L M_#QQY255'GZ6D-RN2O;T*G"OS0)'4DSP4':[4X)IMU^!@==T=;"W\F<6N9O@ M;;T^>=5R :7]VX>T-X3"#7!.Y_V,0SOKYLY_D_S^]?&$M-@8WT>,62[$&RU^ M>RA=1!8^,*UGFE[Z:+@J57\#8;@(9?"E 2[@U0@)G@]W$(^E)G1U,G+PIN:E MZD5QQ2\B8BJR4E*-]ZM_ENT!-\V/;=Q;:I*_>HDM-C]?: KXJN%=1H#RPCW M+/ 8\Z$@+[,YG_/PN -: M8?59[2P%WZOD?%CKM_B1'>]'_D#E$CXP\_A&=NL0(-JRTL$]]_NS]^6S%ZR3 M/U'NH*Y15(E_@Z^S,'NZ?+2^TX>'.GY7'RD,EDX3/K/6#,4=BUFS3 HWU7&J!)\?!9N\"A01%X M7_5K>*CIL/!!=W:6Y.##W4GH_#(7(0R,3L)7ALA0;IJT*[0 MN].A0;)0)WFF#QY\'$+_E/69>L%4Q'5K=(FRUG)SR9_T8#\($7%LH8RLT MEX.=SY*ITRXP2Z^OKT(R=J @][X(8_FL=%,)%125]0;#:^K&4;RC0GU]3-)- M439CGBG(*VN.G8/+UIY[)OO73IJ:F/V9RT?$WTXW M&E2Y #O<>,,R^EDB[\&6G>7HS]1/\ "GZ*$ ET*['I?TK>7H.]'+E]XEDX#L M"#D"D"G #LZT,3G:]E!P28?-,'MRU!1FK)+CHF;Q<6!2:I*-2/ BS>J]*;Y6IJBJ4*8SA8HA3"%SA498R@*GURQ^'MZB! MM<&T82H>#-N.YJ# 3G*UU"DBE5F$Z?OD>"*J:XYUZ&>IJ[NW5Y!7 ,XN,2,U MX%RA3I ["GWYZ*Z>8;B>;NXE&K"NGG:E?2?G[*-')4_8C>1*%4<:MI\_RN9 MJZ@@[^S)NW 5LNQ^]QVNAO,#20B=3VM7Q[]_+J7F(A>V8Q7AE;@S7JKW7QB& MLI6<%>KLN:M^]L2F#Z%(W'U)'/OF7U+)!C$F87F5UKH[* J)3U0K"D<^C*3N M)RH-UW0=*L>0XMO[6?MR02IN;]HLWBW@-:I=^=V\O3UL6GSX/0(2WA/U#+"Z M38/'SX[%D*VX<-6A[5_;C-3Q/+IAA,O[/B65(<1]LO5'3 S%\6.7D'W[>,,! M[DOQ="YC.['3]L?;7_%?&#]?F% ZS&9 9L.W5[.?YTHLUC%R:G!'9A_52#K\ M0GM^T6'CQIK[W$FW,6:TUB#9(^_!0WXU'XW"72DAT1%F:0^+\8O=RN&ZH=_3 MEGCCW_;50CY@/?6X8=4A)YH4;C*>F+\?3;P03])9&$@*!,;RTX^_IG:4KEJ+ MZD8O2S,V25F5Y]XK1O;Z51]&%]4,/'E:ZPQL.ZH&3S"O_"X8=O!8\NW>:!_N< U:0#.\ M>JITI+0EWNTE;J!G&F(6!T-_1^B0_1: \5J7QRAT),56ZG72_(M&?9A(1BT^ M^?C(FZ]'>AG,E MK\)R%,3<-\=NO:#DQ I;RNNI/_[&=8)IFMY@9H.9%PY_>H7,V=$ [[0NA=T4)R7:(60ZJ#TQ')!! MM)F$=H8,#2 95P5[* #Q@^2&8?5RG>R"D /)UZF)R3%RPX2?])8>KDK3Z1Y> M]2.XKG!OM]"1?('#0]%U4[N1@(+Z5CTY2,7[R>S.+=?,LOQRQ"R/YXDWF\4;*,S2 ,1'^3=0E M$IW\U2+J":>'7ZYZ*U;;-\4L(5\D/R'52+G!C:1Y'$H#]'A7#QRK@R<.:( [ MX?W5U 3RZ<8G/FI";9]LH?XRVQ;8'99<-OR M.R6.S<2@?)T0PG6Q.R/,/;HU F1;&J 2$R<-LL7_2%E6GF4>CZ4H%]Z^))SR M'?;D@O:K<*%5W-OO!.]S?8W@KMX9C'HQ%%K\^ I:+[_6$E(0FGE0=/@Q/.K7 MFUXW7(Y7"CDJ*M*AJ7/F/;R(S%#,!MF%$(,D>CRV74UFF[(R4>&S>>K#IW6' M1A+-H9.X!>B+ZHM[R!C&?(0$T:4Z=SK;]"-\Q:B*O$@:.I**=]Q5JFEA?5 S MG)OIGK33FB]\V6\=[IQI342V)BS&57)KA/;FB7YN&(4DY#&>R4I/H0%@:>N> MP7CAS2,B_'WR>T)7PB'XP@/)HK=WA&(BAXHWAQ-M2KSEVWR-"PK*RS'G/BS4 M?\K)^.P(I/!Y>GJYD(KW0RHJHV]YW@)/+A+.H]%5XD)Q/5+[?B8A, MXC:U8/EJ+3!XU1_[^O%NMK>/,D[EN!92.M^7"S6$=ZHGF7(7ZSZ0-W@:,*AE M?5J[78B_D?A+%TTF[5LS5=F!,52^\#;H!>5Y%IORDS9/?K7O>UOV[;Q9^:[\ MAA_)H05M70+!P[ _U=(*W;/I%VX>QP)_WT\6UP?C6ZMG22&#R#I MFZ_#Q?:A9$MB@!ZQ,VF>]0F5G6R/LW82R!N2*E6T+Q^A*#[*^M'0T=BZ."H+ MTE7^L3O7+1=2GQ42(OW-"(FBF**6)\NX%N$QG':8_>I[7I#FP5L0!MDCN,V%F@UC?0O4M,(3%?YE*/.[F'=HICQR6BV MNV;::Y8&N XEWLL^'GC10K1*OD!F;%5592-[;!!:MLX298\&'Z<$C2#..[-V M<)?(_$2_>OM)J\N/B--M8+^EJ)21W6^3"IVG*@S'L,.9[56^#<&7GO>2L*NE M3E#+99@,YYALXY/TE/04 V'D.?@MPQ/KH[_U"O<(X]-/7'BB?8 MD]/V2/G6K=D=+<^:Z=_KRWURTD$;LC:XA;"E&;+.STLV.':$Q_5HOH_,S +' M )4-'TWYLVS$6R[FC.7=K8FGYN@WQ$U'FK*^4T0$M93(1#$;,^ZNWQQ6H>\9IF MQC8MA?X=*+N?^IR %#;W<8M%L!"T(*Y1=WA*SZ!)&*9Z$(+H\*F-S2"D,"B M$2U:(MFF+*_&8(HVNYQCG^"26(2J6HY(/0A",V]A9N%-\8L^5_P.PY6)_8KG M[1DO#6/-U!!!D$JT^G"F)&IDK5N\4YG=X$O1\#0L=(5R!4,(Z4!>@;OL7R66 MM:\V&G[T1+$B'P"CL]#+KPE;MZP&&PU]%I'L4/+40/M14C5ZPW=R/8.WKPTA M.CCDFL>]PLPV>Y#XE,KTH_XJ(T\[F9(^F,?%U0%_HV>!YAD*E'C&!9%+ _)H M3_1\DE7P@Q6'..DG'2:%Q-$ ECL./\T3'< LWP,L.2S'!#\4K1N;-XW4$RUJ M[*K%0H)\-HH63WFYT/%M:BN8ON5T,>:T\\B"XNR!T:CSGP(-:0!ZAXDUZLW! M,H0(FOS,KGPL4,;$=+C:W4N9&>*.-JR?NB1<7_LEUP&E_.:4W@R2.%ZJ0=MG M0JX]0%]:,>]\>#AJ4Z_M48F]U.F;D!^85G8ERS3MX="!&;C!+US =X6-'!*U M@'CDH2\4S<'(_4S=KL#RO/']- _#W-UG1;M>W7-VLS,4X&FM5X2W(QG!SL@) M_58D*Y6-'$,0_8+?Y@N?F (G*W,WW]BP,Z[4RBUI/;Z%T"&FBB:+IKYS9_1Q M"_JX:K4EV5-YZ]Y;IBOG!8;SSI&3<\F9A"0AE0&LLP2!.*,IR19X4USB]K+: MTSD:0&DE5,(BQG3$(BD?/*Z->5R#@W0V02ZMD4R6:S3FB<%[ T/+'@2:8"" M6DHNPOKD^0/D'OOK$[I?SVB 5-OG-$!Y I2*M@*CMN,%=G+U3S>S?;(;#9!/ MY;/>$V-=^^6,W+]'0/YJ-* 4=Z!VTNI,CL7E:( C%R;KDW+PDLK1RDF>]>;@ MJ0/X<='X'^"E_\0D32XCET1/(=+$/-WADNXV6<:'4K#1 =X'4ON11W>K48.] MU'N-X(U]E]/@VJ%WYP]!9!^B:\O14ULT( MMEAW9[!\233FVUR"NC5@OY0:_Y3L @'Z;(%<*5M[;C[ZE3L^2RMA,AL@,#^. MC9-+[8%OJ5A1R[&=R2CTK::,,$KG*/:D)OP* C0,7G@[7Z6*\P*W/95!O4"P M'DN1!RDB^ TOK2F96[@#_K-$YOX*_+4FV4DA-MNY5;N:USX!Y_XL%C3A]M5Y M-$YRBYZ<\[3O!*%42IU**OF,G^E,C?A[6VHVP3N+4IM^%.GY)Z0.?ARV E>! MC'L^?U.->#MGK\^JZSKA$,.^9O8CN3*F'-<3&.KL;;FY=+%N:N:31*E9"SZ& M6L=O0H7G# M"9&4'[FN?-XRH@>UY6W48.M?X!RM&.7KNMDCP<:!+ X4GH3_&SY/C3DIZDMC8,;.Z1-BS)!PN)#'ID,=)*NVK6 M^HQ-1\-P*_*JLHM*/H$&N.A4("\=?#4/V&Q;W7<]F]%/L^.D'(<[8TA]%78- M88KSTV?"12EJM)!>NZ:ER%*R])F=@7*?F>5BR:Q:+[&_I9!U46@3/#&^ M/T$>/>9$F'\FOR1^<4CQ4MFQ-X1>IVB-;GMGMD+9E<1YN(Z![6.OI>==1V5N MF"GU>5S,OC_D0&D.PV;U(/L1NL3A&)!>MTBZVY4T/S:CP;*+95XQV2U-1FMP M58H=>WA_$1624^URS!6E!20)1$_N@8)YJ]9=APZD[N?,?RYE+):,M\ PVJ4' M-J&%#\..K M.MPO62?/]]V278RB%B]C2.1 54MD<_TFZ1J,_ AO[D,3UHM$: M\R092@QYN74SQ6:K.I=WZ>M,POY!\#;GZ)=N'R4SU4/73@I7KB\KFS6^<4?> MILA(K5]CN-38;K@48N?$8;>>EB\B;J3GEP+=$#M/2C+HRM'4>:G TV,CV8WA MD;5+*]*=0DN^/E:,3#6!=]OY^D?FB_V2F467[I5VI&]5<66$^!IZ!L&"F$*N MCJN,LU4I3L_8?RN]0C3A2 M\8)GV2N_20(]V $9$PPN+"1RN-'HR[&@^*F N MWFGJEV(L8XNIU"<-'/O3 *T\B&A+!3@L1SYL;L6,_7[T_ M9_CM/W@S'0^9,&RQ/AK?0Q&M\0*16F\YK::K+W:K*E)%&G:8"SS/3CZ 'VUI@[G=40S4FQO\[&&J^K7DBT&Y1@C+C_"'&SCD9(/Z MT"?=F>5-70^OI5U;1&W704@,R 1GXY,_"L)PO%GZ5:F<]K@B$!.':RM3F@.G M\/=86CJ%[N)2)+DRE4+-&UJ( SQ$-TY">$I0701KIHM;:J]\KUTI+R?:H#,7 MU#2"JK:8%>%^)AEGU*[?)#DT%B[NMLQ C=IS[G5917%5"R@![>K+%SD]5N!!+JI&W7*)?A=65,W MZA;O>EOK.7\$[J(RE78V\SWT?2.I+,_S\6HI2)?7-RU?HJZ6H=RAA2.7(=V% M&T)*R_'I&4I#2B 7GK=4#+1#F1"AY'S2 &$ YW.=S*;%1V80. _G!5XG"[0W M7T@U(P';PW272:+H EMRY9W!(.;;@4!&LA4W+_QRVS6;UXR9,_0_!2#@RSN( MKNARD/(K%[FZLM*'N1[]41Y!AS#\HH=I#M8B1VA+TBI[*77Y9,0I;IP"7"W% MYX7B#CM58^')C'$XR_PHB\*B*E==B"7FN.OB*,:XK-XX2B3$7698D=V M/@:3Z?'S[>!H(P:8DQ3)^GE7=&"?]L1J1E9! ZR.!'V^%U],7AK"I,P]RY;1 M6W+VJ<8Q<<"=&.$MJ;XA5U;XU-OA4?HW.YVI8%&-[@*C,K)'BV]JC M@@7Y&H$SF95I& '[+B#]KI,JGE(66^?Q MO^1EI$0UD"[%]JQZP[Q6+V8B5? M##S;8^J/,:MR%A_U,R,BHP6(MO-3TPL'7S7I]Q$DKLV(19/+B*=$:*07Z#P> M*K"11=_>)ZB>J7=* 2HHFB7D+GPDB@6)%QH%&7RTL[^]_T;ZYX?:43$3Q6]5 M[%>2UQ7+\N%>1 5F/5_FQ1S@TK[^WP^<< M!ZR^/N\GB=YE?Q_^1H/N.H]DIL=\R@EEG1;E<_UY-P<[]"+27,2'JU"4U.C MW/1;2DL!,'Y&-1%/)H>TIF,)XCUH<(G%A\-"<_3M,M=HC&91L_MPVA*]I%^4 M),RX *UEO)V_'8DP>D[@;1;VZQ,SE$L37=4NL2N5K#Y9KWNIV]U@6K6N=V5= M6SFT:*P1ADMA_;%-%H[9/"$%W#F-.\H6BKA#EB"%M,U='&D4.-9;LSZ:CV_F MI&B?$A/A&M+UMS755:E.)-9HI3X^@V*[NX1SNP?WM%:%'X1ADOFL<>2!2_DQ M/972S+YW MM%J8GXQZO HJ-!HM[I4T3_V1PU?OH6V!WIV$LL*?_PHGL30'Q/1L+#>"\'99 MV(O]!<5X].;L+8OW^AF)\&->2=]BX\LKD8>N:A:6$B>*BV"R.)#">6U_C_P% M#V:F=J"8M23"^_.NQG4:\9NS1,%*W!_2 !;-M<&2" @YBEA)90L3TB5N MLDF\P!F*$K^Z3=2.<^@P"?!DPFT7,J-MF1%NL76;+'Y) >:?L>(#&1)3T5RL M,1V2GW/U ]>M(%F9(K/B>F;8 W@+!\6;=$WS?=0"4R5GZI(LJ'$4:XN=LRY^ M60QEEI2,2Y9*U. J+2A97NHU61\@2V,H'-F$\<[3[1)*KZ6,4*P9I2I0[,D2 MQ"-@#)2S:MKS%IAL1)4@W[Y9,R+0R2N:B<$Y7\ 0',7:7\\-:+UU?RF]K]$T M,$& +41/05\>:<)K7Q,[ ][X_@P2=SUD<8W;)\-4@2[1I2&7,:X)<*5VY8D1MW'/FB21K+ I_2B0YD*I5'LS)^E"7> M&^6W/YH?N5M9 MO%29J9VD 1[T-(H0=X5(9SD(QJJJO1Z/TC%.U=+*!@NSO 'M$A+UHUBGP*)A MS("$*81YU[]>:2&-!I#L;[0BZ:@L2&H)+$WRNQK&^G[/-ZZ1O$)JW'..^9&R M?Q^MS>EL5APCX]G?(POAHVSA-DI#J)?(].N,8-MOO3U MF)BG+BID.[GU <5S(:&E<_4QSQ,YLC=3DJUT$T'B?J*X<4%1B?Z8*T/@HIB! M=8*$1$/X\(2N41L5?W3!9Z&6>V6.H3%&HWVLW<_CFU!B@HAIOVE<9&$C6!.2 MNIR=KY$R5AQ7+'NW3UN^MH\&(!JC3H'-/O8D <%!@$XZ@2>&"9F=I4]I@(ZC M[5C063SZE$>VLYXE5[91I4E_JZ8.?Z_>4MC&-W_8)=O1 ([/M^V676 B.;4< M4K?LTU,$RDD!;3_/D1@5T9V]L>4\P5>5)(;+P##M)HVJ-4<]M+H^>\LSWN 8 M88NTD8>C'V=MB-:<:;[-+A'1C,?T'/JLD&8Q9B9#B[712!<-V:+B+8\> M]JQDP;19F[I.20CCDF\.!R$7S%<.TNEXPUOMB7R"WQ@KCLZ/Q48[["0KO;<< M3E<;1G-Q*TN^;%-R/*S"FD^V>- S^>O*2>3I8/K%W.%%KHZKUNWZN\WG.0J M1Y*2,HDH@BP&SZ,4IF$R^6O]Z;=PZ7)B1U=T]MVASN2@_>*RZL.K\VZ9WUQW MYGWZ?55/89W Z@%3&=N;I9%=X"9?)W^G32/(,Z#W6/]?(!*4,[2<+(GX\UA6 M'<\OWG%R$^MFX]!RS5S2]N,%IS$E*4BF,+)R9F7+XOHIAF1HG!F.=_ARJRMK MA7)5:"&YLXP7V:H/,B6@+E!XR:V+K$RY9Q?8,;&4FT0,02R. I9:LW*?*O#S MS+M.',,6=,MFE8!^<7C'YP/@)10 P?M:+T(H^JS"-W^*BO)8%_5GC10K!-.< M$O$#:Z58E54%E4$MH9)G)-H/,7$CE0YELET$_Z- HLP(.KK,"MR E; XP YG M-0J.9#7-#9JE$XJ1K5Y:%Q!>Y(CC 'B\ U&LM2Q^3ND[])0*M&;?W=NFITB0 M$PFS#/;3%Q$N^QO<>V5,9!>;H:FC/QTZ5G267PJRRRXH*-8.UL:I>8H1"7G7 ME']')O%8K;;;GC,&K64K#9:NEQR-K'?ME8*,!0=/&X/1K.=(4 Z_N-+72^09 MX^L+OAMY&?Q--@&WQ_V3E26#V%-6HE.66E22#>R/XDZJE!Q=H" A?N3HD>,W^8 M<*K7:FJP_D(MY=H:,9[0A8,F@*M1S MMAXA&)66!6Z=W!\GW3Y)0-)&?[\U M,T"5H$B1PTAE7[7$R%"225N622*"?O&ZBI%4NQ;?V -%VWF[RI(*#0U0B(KU MOK5\P7[M_5,U4[Z@O.%N'&ZD.Z!D/"8 HCYFZ/110!'79YQ[]Q8$N ,K[C0- M2?@P\RC+B]_;)W7I+=7>7JS?W;S=]4VLV@A&&=X=GGA+K=NVT\! :_+45R)Z?D(0N>&R9=,DZ%F M83O[JPR9->S3'BDWSMA+O:V= 1^,1\]#6*[U^X[LS*DN]0;$=HC9#<$A90U^ M9GD\33-B/$,M.+,TF?,4>@)F$*R&>[B^3+F$>'S&WW]?U9"-^1J2+Y])=\K M ))N9)_C:;R+C-22(;K%(>?1C@K?B7DU9 MQV]6:>I'FRD("@F5E>VQ0+-=#VNN/]PIJB+96/W*O:37""9*RA:$'YP2VD,N MQ84YP6Y2,MT;?-']CD()-UTNY7RWHMA0VW/]-PDDX# M_"YM.+#=2;023!\.6F_@P@U<@TF53LS:K?&+CR^ M)$-: @$&!=#,M+1A/"/99$@ ]]3!JS6]TH'STJ<;/6L#;)#P?E-_-&=?[+L? M(];2[W(]8'.CL+JNN3)1&@ =G@AZENT+O3+T9V56!GZSS?<=85W;--%6RX[3 MPJ5/R[TW([+:=%\Q >V.'SS!1V31 /+)O[[)@0<.5ZX [I_Q.K>".EY]?GA! MH"=WX@+=XJ'?H0OWATT 0!/);K(K0T5J'P"$M%J>"QTJT "HD:8_'(*WMOMN M<)R=WTC-"V/Q5XP+H4,.'.X5G '0#8#CV<&"78?F=1?H: "Q/1Z>$_>F/^0T M-=4VY8?/JBWRISG^43=P2 -H2@"R]5N\_0.ZL/W&BKI?'5AR"^GD-&D Q=0] M]6Z^05_F?/45ZI$:I9;NR/P+G4HRLO4-:Z\OU<*1!K"BNWL:#3[+L['W MCHDYI*V9AW3GS'1[,_]WBLZ3=\]]/L%X@RLNT@L_OYKOX_L'>YA4/FM\A[/( M0#36+.=+IUD\#=!MIU"L'174:\>6@VQ,I6R?A',?B>' ,4Z\]5SAUXE<+WXQ MEJQL:0"CE)@E%X7>[VY*W\@$G_(@^Z>''UWC8BK;"5(C,3"+G,R9'^-[!VZ& MYR/R93V4L&V.B]P8LLA)N&:3[_6;_[N74Z_0T2;_#U!+ 0(4 Q0 ( .D[ M>%)5;T:"KB4 *I3 0 - " 0 !E>%\R,S,V,CDN:'1M M4$L! A0#% @ Z3MX4M:TT\F% P DPX !$ ( !V24 M &UB'-D4$L! A0#% @ Z3MX4@S4TW3X! #"\ M !4 ( !C2D &UB%("L>Q^) 8 0_ 5 " ;@N !M8G)X M+3(P,C$P,S(T7VQA8BYX;6Q02P$"% ,4 " #I.WA2N?$/)Y,$ #5+P M%0 @ $/-0 ;6)R>"TR,#(Q,#,R-%]P&UL4$L! A0# M% @ Z3MX4DOP:LBF#@ ]&( !0 ( !U3D &UB